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Abstract
Background: Oxytocin and the oxytocin receptor have been demonstrated in the gastrointestinal
(GI) tract and have been shown to exert physiological effects on gut motility. The role for oxytocin
in the pathophysiology of GI complaints is unknown. The aim of this study was to examine genetic
variations or polymorphism of oxytocin (OXT) and its receptor (OXTR) genes in patients with GI
complaints without visible organic abnormalities.
Methods: Genetic variants in the OXT promoter region, and in the OXTR gene in DNA samples
from 131 rigorously evaluated patients with Irritable Bowel Syndrome (IBS), 408 homozygous
subjects referred for lactase (LCT-13910 C>T, rs4988235) genotyping, and 299 asymptomatic
blood donors were compared. One polymorphism related to the OXT gene (rs6133010 A>G) and
4 related to the OXTR gene (rs1465386 G>T, rs3806675 G>A, rs968389 A>G, rs1042778 G>T)
were selected for genotyping using Applied Biosystems 7900 HT allele discrimination assays.
Results: There were no statistically significant differences in the genotype or allele frequencies in
any of the SNPs when IBS patients were compared to healthy controls. Among subjects referred
for lactase genotyping, the rs6133010 A>G OXT promoter A/G genotype tended to be more
common in the 154 non-persistent (27.3%) subjects than in the 254 lactase persistant (18.1%)
subjects and in the healthy controls (19.4%) (p = 0.08). When direct comparing, the A/G genotype
was less common in the OXT promoter region in controls (p = 0.09) and in subjects with lactase
persistence (p = 0.03) compared to subjects with lactase non-persistence. When healthy controls
were viewed according to their own LCT-13910 genotypes, the C/C lactase non-persistent
controls had a higher frequency for the OXT promoter A/G genotype than LCT-13910 T/T lactase
persistent controls (41.2% vs 13.1%).
No significant differences in frequencies of the investigated OXTR SNPs were noted in this study.
Conclusion: The results suggest that polymorphism in the promoter region of the OXT gene is
most common in subjects with lactase non-persistence. This polymorphism may not be related to
GI symptoms, as it is related to lactase non-persistence also in healthy controls.
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Background
Gastrointestinal (GI) complaints in the form of abdomi-
nal pain and altered bowel movements are very common
in the population, and in most cases, remain unexplained
despite extensive diagnostic evaluations. These patients
are classified as suffering from functional bowel diseases
[1]. Frequently indistinguishable symptoms are seen in
the subgroup of patients with lactase non-persistence,
which is also common in the adult population [2,3], and
reported complaints in this group are surprisingly less cor-
related to the volume of milk intake, than previously
assumed [4]. Differences in gastric emptying and individ-
ual perception of symptoms have been discussed [5,6].
Many neuropeptides, e.g. serotonin and norepinephrine,
are involved in the regulation of GI sensitivity and motil-
ity, and polymorphism in these peptides has been sug-
gested as another possible explanation to symptoms [7-9].
Oxytocin was long thought to be a hormone primarily
involved in parturition and suckling. Recently, oxytocin
expression has been found in the gut [10,11], where it is
secreted after a fatty meal [12] and stimulates colonic
activity [13]. It has further been demonstrated that sys-
temic administration of oxytocin leads to enhanced gas-
tric emptying [14,15] and that the oxytocin receptor
antagonist atosiban significantly delays gastric emptying
[16]. In accordance to this, diabetic patients with gastro
paresis have no demonstrable postprandial oxytocin
release [17].
The aim of this study was thus to examine whether genetic
variation or polymorphism in the OXT or OXTR genes
may explain the pathology in numerous patients with GI
complaints without organic explanation.
Methods
This study was performed according to the Helsinki decla-
ration and approved by the Ethics Committee of Lund
University.
Study Population
One hundred and thirty-one patients (108 females),
mean age 38.2 ± 15.1 years, range 20-78 years, who have
undergone rigorous evaluations for GI complaints at terti-
ary care centres in Malmö (N = 43) and in Gothenburg (N
= 88) were included in the study. LCT genotyping was per-
formed, and 13 patients were found to have LCT-13910
C/C, 76 patients had LCT-13910 T/T and 38 patients were
heterocygotes. In the absence of evident organic disease,
and as the patients with LCT-13910 C/C had persistent GI
complaints after elimination of milk products in the food,
they were regarded as having irritable bowel syndrome
(IBS) (1, 3). They had predominantly constipation (N =
35), diarrhoea (N = 35) or mixed symptoms (N = 59),
whereas clinical subgroups were not defined for 2
patients. Samples and written informed consent for this
study were obtained from these patients and from 299
healthy adult blood donors (99 females), mean age 64.5
± 13.0 years, range 41-85 years, who negated all forms of
abdominal pain or abnormal bowel habits on a written
questionnaire.
Remnant samples submitted from an additional 319 sub-
jects from predominantly primary care centres to screen
for potential lactase non-persistence by analysis of LCT-
13910C>T (rs4988235), and who had had homozygous
C/C or T/T genotypes were also included in this pilot
study. After initial registration of age, sex and genotype, all
personal identifiers associated with the samples were
destroyed. This procedure is in accordance with the Swed-
ish biobank law. These samples were put together with the
89 patients from tertiary care centres with either homo-
cygous for C/C or T/T. Of these totally 408 subjects, 154
(mean age 30.5 ± 18.2 years, range 3-76 years, 113
females) were LCT-13910 C/C homozygotes for lactase
non-persistence and 254 (mean age 36.8 ± 19.3 years,
range 2-81 years, 189 females) were LCT-13910 T/T
homozygotes for lactase persistence. Heterozygous C/T
samples were excluded from this study to avoid ambiguity
in interpretation. Although the samples were not consist-
ently tested for adjacent LCT variants, e.g. LCT-13907 C>G
and LCT-13915 T>G, these when rarely present, are fre-
quently noted outside of the main LCT-13910 C/C or C/T
clusters. This is seen in 1-2% of samples at our laboratory
and was not expected to interfere with interpretations of
our results.
SNP selection
The OXT gene is located on chromosome 20p13 [18] and
the  OXTR  gene is located on chromosome 3p26 [19].
Some transcript variants have been identified in these
genes. We conducted an extensive search using Entrez SNP
[20] and HapMap genome browser [21] databases for
known SNPs in and immediately up- and downstream of
the OXT and OXTR genes. Five SNPs with heterozygosity
of  ≥ 5% were identified; the OXT  promoter region
(rs61333010 A>G), the OXTR  5'promoter region
(rs3806675 G>A), the OXTR 5'hap marker (rs1465386
G>T), the OXTR exon 1 (rs1042778 G>T) and the OXTR
exon 4 (rs968389A>G).
DNA analysis
DNA was extracted from fresh EDTA whole blood using
QiaAmp minikits (Qiagen GmbH, Germany) according to
the manufacturer's instructions. Genotyping of all SNPs
was performed according to the standard protocol at the
Department of Clinical Chemistry at Malmö University
Hospital, using commercially available SNP genotyping
(Applied Biosystems) on an Applied Biosystems 7900 HT
instrument, no UNG mastermix and the recommendedBMC Gastroenterology 2009, 9:90 http://www.biomedcentral.com/1471-230X/9/90
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PCR program. Specific assays were C_30100478_10 for
rs6133010, C_7622000_0 for rs968389, and
C_7622140_30 for rs1042778. Assays by design were
acquired for rs4988235, rs14653886 and rs3806675. All
samples, including the primary care subjects were then
analysed with all assays in the LCT, OXT and OXTR genes.
Statistical analyses
Fisher's exact test was used for comparison between
groups, and odds ratio (OR) and confidence interval (CI)
were calculated. Mann Whitney U test was used for calcu-
lations of differences in ages between groups. P < 0.05 was
considered statistically significant.
Results
When comparing IBS patients from tertiary care centres to
healthy controls, no overall statistical significant differ-
ences were observed in genotype or allele frequencies
(data not shown). There was no association between
symptoms and genotype in any of the selected SNPs in the
OXT  and  OXTR  genes (Table 1 and 2, other data not
shown).
As genotypes in patients with known IBS did not differ
from controls, we examined whether there were any dif-
ferences between subjects with or without lactase persist-
ence, according to their OXT or OXTR genotypes. There
was no difference in age between the lactase non-persist-
ent or lactase persistent group (p = 0.39), whereas there
was a significantly higher age in the controls compared to
both subject groups (p < 0.00). When the whole study
population was included, there was no difference between
females and males, or between presumably pre- or post-
menopausal subjects (age < or > 50 years of age) in rela-
tion to the selected SNPs in the OXT and OXTR genes
(data not shown).
When the controls were compared to lactase-persitent and
lactase non-persistent subjects, there was a tendency to
significance in the genotype frequency in the OXT pro-
moter region (rs6133010 A>G) (Table 1). When compar-
ing allele frequencies, there was no significant difference
(Table 3). Calculation of odds ratio and confidence inter-
val for the allele frequencies showed no difference
between controls and lactase persistent subjects (OR:
0.89; CI 0.50-1.58; P = 0.77), or between controls and
lactase non-persistent subjects (OR: 1.49; CI: 0.83-2.69; P
= 0.21).
Although there was no difference in allele frequencies for
rs6133010 A>G (OR: 0.60; CI: 0.32-1.11; P = 0.11)
between LCT-13910 C/C or T/T subjects, T/T (lactase per-
sistent) subjects were less likely to have the A/G genotype
for this SNP in the OXT promoter region (P = 0.03). A
slightly lower frequency of this A/G genotype was also
seen in healthy controls compared to lactase non-persist-
ent (LCT-13910 C/C) subjects (P = 0.09), with no differ-
ence between controls and lactase persistent subjects (P =
0.86). The frequency of the A/A genotype in the different
study groups is shown in Table 1. When regarding the
asymptomatic blood donors according to their LCT geno-
type, the frequency of LCT-13910 C/C was 8%, similar to
the IBS patients from the tertiary care centre (10%). The
lactase non-persistent asymptomatic controls had a fre-
Table 1: Genotype frequency of the oxytocin (OXT) promoter region rs6133010 A>G in patients, subjects and controls
Genotype A
N (%)
A/G
n (%)
G/G
N (%)
P value
Constipation-predominated IBS (n:35) 30 (85.7) 5 (14.3) 0 (0.0)
Mixed IBS (n:59) 49 (83.1) 10 (16.9) 0 (0.0) P = 0.60*
Diarrhoea-predominated IBS (n:35) 26 (74.3) 9 (25.7) 0 (0.0)
Lactase persistence (n:254) 208 (81.9) 46 (18.1) 0 (0.0)
Lactase non-persistence (n:154) 111 (72.1) 42 (27.3) 1 (0.6) P = 0.08**
Controls (n:299) 240 (80.3) 58 (19.4) 1 (0.3)
* = Comparisons made between subgroups of patients with Irritable Bowel Syndrome (IBS).
** = Comparisons made between controls and lactase persistent- and lactase non-persistent subjects.
Fisher's exact test.BMC Gastroenterology 2009, 9:90 http://www.biomedcentral.com/1471-230X/9/90
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quency of the rs6133010 A/G genotype in 41%, compared
to 13% in the lactase persistent controls.
In the OXTR 5'promoter region (rs3806675 G>A) there
was a trend towards higher A/A genotype in relation to G/
G genotype in lactase persistent subjects compared to
non-persistent subjects (Table 2), although allele frequen-
cies did not differ between the groups (OR: 0.72; CI: 0.48-
1.08; P = 0.12).
There were no differences in genotype or allele frequen-
cies in the other parts of OXT or OXTR genes examined
(data not shown).
Discussion
Among patients with unexplained GI complaints referred
for lactase (LCT-13910 C>T) genotyping, a significant dif-
ference was found in genotype frequency of a SNP in the
OXT  promoter region gene between LCT-13910 C/C
(non-persistent) and T/T (persistent) subjects. This poly-
morphism was observed also in asymptomatic controls
when these were divided according to C/C and T/T.
The symptoms leading to admission for lactase genotyp-
ing is abdominal complaints after lactose intake in the
form of abdominal pain and bloating, diarrhoea and an
excess of gas. These symptoms are often impossible to dif-
fer from functional bowel diseases without making a gen-
otyping. Patients referred for lactase genotyping who do
not carry the lactase non-persistence genotype, may in the
majority of cases suffer from functional bowel diseases
[1]. Even among lactase non-persistence subjects, many
patients suffer from functional bowel diseases, and
although reducing the milk intake, the symptoms persist
[4]. In the present study, we chose only homozygote
patients to obtain well-defined groups concerning lactase
persistence, as individual variations in the lactose absorp-
tion, particularly among heterozygotes have been
reported [2,4]. Factors causing this variation of symptoms
in response to the same volume of milk intake, or accord-
ing to different milk products, may include the amount of
lactose not absorbed in the gut, differences in the bacterial
flora and their metabolism of lactose in colon [22], and
the rate of gastric emptying and individual perception of
symptoms [5,6]. In the present study, the A/A genotype of
rs6133010 in the promoter region of the OXT gene was
more frequent in asymptomatic controls and in lactase
persistent subjects than in lactase non-persistent,
although statistically significant only in persistent sub-
Table 2: Genotype frequency of the oxytocin receptor (OXTR) 5'promoter region rs3806675 G>A in patients with lactase non-
persistence or lactase persistence
Genotype G/G
n (%)
A/G
n (%)
A/A
n (%)
P value
Constipated-dominated IBS (n:34) 11 (32.4) 18 (52.9) 5 (14.7)
Mixed IBS (n:59) 15 (25.4) 33 (55.9) 11 (18.6) P = 0.44*
Diarrhoea-dominated IBS (n:35) 13 (37.1) 20 (57.1) 2 (5.7)
Lactase persistence (n:254) 69 (27.2) 128 (50.4) 56 (22.0)
Lactase non-persistence (n:154) 55 (35.7) 76 (49.4) 22 (14.3) P = 0.07**
Controls (n:299) 101 (33.8) 146 (48.8) 52 (17.4)
* = Comparisons made between subgroups of patients with Irritable Bowel Syndrome (IBS).
** = Comparisons made between controls and lactase persistent- and lactase non-persistent subjects.
Fisher's exact test.
Table 3: Allele frequencies of the oxytocin (OXT) promoter 
region rs6133010 A>G in controls and in subjects with lactase 
non-persistence or lactase persistence
A
n (%)
G
n (%)
Lactase persistence (n:254) 231 (90.9) 23 (9.1)
Lactase non-persistence (n:154) 132 (85.7) 22 (14.3)
Controls (n:299) 269 (90.0) 30 (10.0)
Fisher's exact test. P = 0.24BMC Gastroenterology 2009, 9:90 http://www.biomedcentral.com/1471-230X/9/90
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jects. This suggests that the A/A genotype regulates the GI
physiology in a different way compared to A/G. However,
when comparing the LCT-13910 genotype in asympto-
matic controls, C/C homozygous controls had the highest
A/G frequency of all groups. Although the small sample
size, this finding suggests that A/G may not be an impor-
tant factor for the symptomatology, but is coupled to
other factors such as LCT-13910 C/C.
During the last years, further genotypes associated with
lactase persistence/non-persistence, e.g. LCT-13907C>G
and LCT-13915T>G, have been described [23]. These gen-
otypes were not tested for in the actual study. However, as
these genotypes are uncommon, and only a minority of
the population in Sweden comes from the part of the
world where these genotypes are most frequent, this may
not obscure the picture.
Previously it has been suggested that oxytocin play a role
in the regulation of GI physiology as it has been found in
both the myenteric and submucous ganglia in the human
GI tract [11]. It is released in response to a fatty meal [12]
and has been shown to accelerate gastric emptying
[14,15], whereas the oxytocin receptor antagonist atosi-
ban inhibited gastric emptying [16]. Furthermore, oxy-
tocin stimulated colonic peristalsis in healthy women
[13]. On the other hand, studies in animals have shown
that oxytocin inhibited gastric emptying [24] and contrac-
tile motility of the proximal [25] and distal colon [26].
Possible explanation to these divergent results are differ-
ences in methods i.e.; dose and administration of oxy-
tocin, in species studied, or in the region of the GI tract
examined. Nothing has been described about the role of
oxytocin in the pathophysiology of disturbances of GI
motility.
Abdominal pain is the most frequent complaint among
GI disturbances. Continuous infusion of oxytocin signifi-
cantly elevated thresholds for visceral perception of
colonic discomfort in patients with IBS [27], and
increased the threshold for peripheral pain in rats [28].
Nasal administration of oxytocin had a positive effect on
abdominal pain in patients with IBS [29]. Altogether, this
suggests oxytocin to be involved in pain regulation, which
is further supported by the expression of the peptide in the
dorsal root ganglia [30] and its widely spread presence in
the central nervous system [31].
Estradiol regulates the OXT-gene expression in rat uterus
[32]. Recently, it has been shown that estradiol upregu-
lates the oxytocin receptor in the enteric plexus of colon in
rats and increases the colon sensitivity to the excitatory
effect of oxytocin on colon motility [33]. Females have
higher levels of oxytocin and estradiol than men [34], and
IBS is more common in females than in men [35]. In
female patients suffering from IBS, blood estradiol and
oxytocin levels were significantly lower than in control
groups [36,37]. As many GI complaints debute at an age
when the estradiol levels fall, lower expression of oxytocin
receptors has been one hypothesis for the etiology of GI
disturbances. However, differences in hormonal plasma
levels may be secondary, and not causal. When comparing
the genotype frequency in IBS patients in the table over
rs6133010 A>G, the OXT gene promoter region which is
closely coupled to estradiol [32,38], it seems as though
patients with mixed IBS have similar frequencies of the
genotypes as healthy controls, and diarrhoea-dominated
IBS patients resemble subjects with lactase non-persist-
ence. This finding raises the hypothesis that the symptoms
in patients with lactase non-persistence, irrespective of
milk intake, may depend on genetic factors resembling
IBS patients with diarrhoea. This should be further evalu-
ated in larger studies. However, we could not find any
association between gender and polymorphism in the
examined SNPs.
A limitation of this pilot study is the small sample size,
and our lack of information concerning specific symp-
toms in subjects referred for LCT-13910 genotyping from
the primary care centres. As people from northern Europe
have a higher prevalence of lactase persistence than peo-
ple from southern Europe, Africa and Asia [39], we can
assume that the group of lactase non-persistent subjects
contained a larger proportion of subjects with a non-Nor-
dic background. These differences in ethnicity can possi-
bly explain the genetic variation to some extent.
Alternatively, the OXT  promoter G allele may lead to
increased pain, and thus increased medical evaluation, in
patients with lactase non-persistence.
Conclusion
Our investigation has shown significant differences in
genotype frequencies of a SNP in the promoter region of
the OXT gene in patients with lactase non-persistence. The
role of this polymorphism in the pathophysiology and
symptomatology of GI complaints remains obscure, as
the polymorphism was also present in healthy LCT C/C
homozygous controls.
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